Abstract: The present invention provides methods for inhibiting respiratory complex III in a cell. The present invention also provides methods for treating cancer in a subject.

Abstract: A 2-amino-4-(4-bromophenyl)-6-ethoxypyridine-3,5-dicarbonitrile as an antibacterial compound, its synthesis, and its use as an antibacterial agent.

Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist.

Abstract: The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate.

Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting flaviviruses, filoviruses and/or coronaviruses.

Abstract: The disclosure relates to (2-{4-[(2,2-dimethylpropanoyl)oxy]-1H-indol-3-yl}ethyl)(methyl)azanium chloride (4-pivaloyloxy-N-methyltryptammonium chloride), crystalline 4-pivaloyloxy-N-methyltryptammonium chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-pivaloyloxy-N-methyltryptammonium chloride, to compositions containing the same, and to methods of treatment using them.

Abstract: Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses. Also provided are methods of making pharmaceutical compositions containing these compounds. The present disclosure also describes methods of use for the alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, and pharmaceutical compositions containing these compounds for the treatment of disease in a subject.

Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.

Abstract: A 4,5-bis(4-bromo-phenyl)-1-hexyl-2-(2-methoxyphenyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: Disclosed herein is a composition comprising a biologically active agent; a base oil; an additional oil that is soluble in the base oil with a partition coefficient for the biologically active molecule that is at least twice that of the base oil; where the base oil and the additional oil are present in the composition in an amount effective to reduce the amount of the biologically active agent in an aqueous phase to less than 80 wt % of the amount with just the base oil present in an otherwise identical composition at the same total oil loading; a non-ionic surfactant; and water.

Abstract: The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.

Abstract: A 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.

Abstract: Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.

Abstract: Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.

Abstract: The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed.

Abstract: The present invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration, among others. The method includes treating a patient suffering from a retinal vasculopathy by administering to the patient a therapeutically effective dose of a compound as disclosed herein.

Abstract: In an embodiment, the invention is directed to prodrug compounds of L-BHDU according to the chemical structure I: Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group; R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group; R1a is independently a C6-C30 alkyl group, often a C12-C22 alkyl group, often a C14-C20 alkyl group or a C16-C18 alkyl group, often a C16 or C18 alkyl group; R2a is independently a C1-C12 alkyl group, often a C2-C6 alkyl group, a C3-C4 alkyl group, an isopropyl, t-butyl or sec-butyl group, or an isopropyl or t-butyl group; Each j is independently 1-6, 1-3, often 1 or 2; Each k is 0 or 1; Each n is independently 1-6, 1-4, 2-4 or 2 or 3; or A pharmaceutically acceptable salt, solute or polymorph thereof. Additional embodiments are directed to pharmaceutical compositions based upon the disclosed chemical compounds and methods of treating or reducing the likelihood of VZV, HSV-1 or HSV-2 infections.